First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients

Janíková, Andrea; Chloupková, Renata; Campr, Vit; Klener, P; Hamouzova, Jitka; Belada, David; Procházka, Vít; Pytlík, Robert; Pirnos, Jan; Ďuraš, Juraj; Móciková, Heidi; Bortlíček, Zbyněk; Kopalova, Natasa; Mayer, Jiřı́; Trněný, Marek

doi:10.1007/s00277-019-03694-y

Cited by 24 publications

(15 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These entities are characterized by either the presence or absence of an ALK translocation. It has been reported that ALK+ ALCL has a better prognosis compared to ALK−, with a 5-year overall survival (OS) of 70-80% versus 40-60%, respectively, [1][2][3]. Furthermore, more than 30% of ALK+ ALCL patients relapse [4,5].…”

Section: To the Editormentioning

confidence: 99%

STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma

et al. 2020

Self Cite

View full text Add to dashboard Cite

Section: To the Editormentioning

confidence: 99%

STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma

et al. 2020

Self Cite

View full text Add to dashboard Cite

“…Retrospective studies suggest that outcomes may be better than historical data with CHOP. [3][4][5] In a prospective trial, the Nordic group evaluated the role of autologous stem cell transplantation after patients achieved a CR/partial response with CHOEP. 6 At a median follow-up of 5 years, the 5-year progressionfree survival (PFS) and overall survival (OS) rates for AITL were 49% and 52%, respectively, and 38% and 47% for PTCL-NOS, respectively.…”

Section: Patient Case Study 1: Peripheral T-cell Lymphomamentioning

confidence: 99%

Patient Case Studies and Panel Discussion: Lymphoma

2019

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

A heterogeneous group of diseases, lymphomas encompass a range of diagnoses that call for varied treatment approaches. Although some lymphomas require minimal intervention for cure or remission, others can be very difficult to treat and are associated with poor outcomes. At the NCCN 2019 Annual Congress: Hematologic Malignancies, a panel of experts used 3 case studies to develop an evidence-based approach for the treatment of patients with lymphomas. Moderated by Ranjana H. Advani, MD, the session focused on peripheral T-cell lymphoma, primary mediastinal large B-cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma.

show abstract

“…Cutaneous lymphomas exhibit various clinical, histological, immunophenotypic, and genetic features. Moreover, they differ in prognosis and treatment from systemic lymphomas with similar histological features [ 5 , 6 , 7 , 8 ]. Up to 75–80% of cutaneous lymphomas originate from T-cells, and only 20–25% from B-cells [ 9 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical Remission in a 72-Year-Old Patient with a Massive Primary Cutaneous Peripheral T-Cell Lymphoma-NOS of the Eyelid, Following Combination Chemotherapy with Etoposide Plus COP

et al. 2020

View full text Add to dashboard Cite

Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is the rarest subtype of primary cutaneous lymphoma, accounting for approximately 2% of cutaneous lymphomas. The rarity of primary cutaneous PTCL-NOS means that there is a paucity of data regarding clinical and histopathological features and its clinical course. This malignancy is an aggressive and life-threatening hematological malignancy that often presents mimicking other less severe plaque-like skin conditions. Due to the nonspecific nature of these lesions, CD4-positive cutaneous T-cell lymphoma (CTCL) is often misdiagnosed as either mycosis fungoides or Sezary syndrome. We describe a patient who presented with a large tumoral mass in the right frontal area, with involvement of the right upper eyelid and the ocular globe, causing loss of vision greatly impacting the quality of life. Biopsy revealed primary cutaneous PTCL-NOS, treated successfully with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus etoposide combination chemotherapy. As elderly patients are indicated to receive attenuated doses of chemotherapy, CHOP-based regimens represent viable options.

show abstract

First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients

Cited by 24 publications

References 32 publications

STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma

STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma

Patient Case Studies and Panel Discussion: Lymphoma

Clinical Remission in a 72-Year-Old Patient with a Massive Primary Cutaneous Peripheral T-Cell Lymphoma-NOS of the Eyelid, Following Combination Chemotherapy with Etoposide Plus COP

Contact Info

Product

Resources

About